When a Proven Track Record Meets Start-Up Spirit
Bentley Endovascular Group AB specializes in the development, manufacture and marketing of minimally invasive vascular implants and devices and is the European market leader for balloon-expandable covered stents. The original business was founded in 2009 by the Swedish serial entrepreneur Lars Sunnanväder and Miko Obradovic and is located within the Hechingen Medical Valley in Southern Germany, operating under the name Bentley InnoMed GmbH. Bentley has been growing its business and product portfolio ever since the launch of its first product in 2012. Today, the Group ranks as one of the leading providers of products for endovascular treatments, serving customers in more than 80 countries through direct and indirect sales.
We are continually expanding our business for large markets such as the USA, which we expect to enter in 2027.
In 2023, the Group has brought on board Keensight Capital, A.P. Møller Holding, and Bonit Capital as new investors. The founders and management retain control and hold the majority of the capital and the votes in Bentley Endovascular Group AB.
Structure of Bentley Endovascular Group AB
The holding company Bentley Endovascular Group AB, headquartered in Stockholm, Sweden, holds and controls its German subsidiary Bentley InnoMed GmbH, as well as the swiss based Bentley Switzerland AG.
Bentley InnoMed GmbH is based in the medical technology stronghold of Hechingen in Baden-Wurttemberg, Germany. The company develops, manufactures and markets implants and catheters for the endovascular treatment of peripheral vascular and aortic diseases. The company has achieved a market-leading position in balloon-expandable covered stents in Europe and is globally active.
Acquired in mid-2023, Bentley Switzerland AG is a Swiss specialist in dilatation balloons and key supplier of essential components to Bentley’s product portfolio.
Group Profile and Background
The Group is marked by in-depth medtech know-how as well as a management team and organization committed to its unique entrepreneurial culture, the Bentley style. It is based on the claim “differentiate to win”.
As highly recognized medtech tech brand, Bentley combines best-in-class customer services with product innovation, thus steadily contributing to progress in the minimally invasive treatmemt of vascular diseases with ramp-ups of new products and applications.
In 2023, Bentley generated more than EUR 80 million in sales. Bentley Group remains on a path of continued strong but profitable growth based on market penetration, product innovations and access to new markets.
Bentley’s products are distributed in more than 80 countries worldwide, with more than 440 employees group-wide committed to a strong culture of innovation driving the business.
Sales Growth Bentley GmbH > 20% CAGR over 6 years
Vision and Mission
Throughout Bentley's 15-year history, we have successfully maintained our start-up culture and entrepreneurial spirit, driving our business development and continuous expansion.
Our clearly defined mission and vision have served as a guidepost for management and every individual team member, enabling us to establish the company as one of the leaders in innovative products for the endovascular treatment of peripheral vascular and aortic disease.
Bentley Endovascular Group AB:
Strategy
Our proven business model has been based on the strategic plan for 2019-2022, which built a strong foundation for continued growth.
This sustainable business model has now been refined into a profitable growth strategy for the Bentley Endovascular Group 2023-2026.
We will keep on developing best-in-class products and services and adding to our niche-focused product portfolio, which will be backed by a strong development pipeline and indications roadmap in the coming years.
Our self-challenging organization will continue to drive innovation, profitable growth and value creation for our stakeholders while staying true to our mission and values.
BeInnovative
We concentrate on the development of unique products and strive to find creative answers to the questions facing the healthcare sector.
BeResponsible
We take care of better health, our region and the environment. Every member of our team is motivated to make an important contribution to the quality of life.
BeDedicated
A keen customer focus and adherence to international standards help us to guarantee products and services of unsurpassed quality.
BeEffective
We strive for time- and cost-efficient solutions in order to satisfy the multifaceted interests of our customers and patients around the world.
Goals
The Next Era of Growth
In 2022, we launched the next era of growth with far-reaching strategic decisions. By adding a new product, the BeBack catheter, to our product range, we are paving the way for exploiting the growth opportunities in the peripheral interventional market.
In June 2023, we acquired the Swiss medtech company Bentley Switzerland AG, a reliable key supplier for us for many years. With this acquisition, we strengthened our supply chain by nearshoring.
With seven product lines, we are now able to provide our customers with a high-quality, diverse range of lifesaving products. Our business is expanding and preparing to enter new major markets, such as China and the United States, which we expect to enter in 2027.
While consistently striving to expand our product portfolio and registrations, we are internally working on an IPO readiness process aimed at the Nasdaq Stockholm First North Premier segment, which comprises numerous life sciences and tech growth companies.
Strong Underlying Market Trend
Our organic growth is propelled by the megatrend of an aging population subject to rising cholesterol levels and increasingly requiring endovascular treatment of aortic and peripheral diseases.
We are operating in an oligopolistic industry. The market provides for more than 9% organic CAGR in our segments, driven by soaring stent demand.
The corresponding addressable total global market value for covered stents and peripheral CTO* devices is projected to grow from USD 800 million in 2022 to USD 1,400 million by 2028.
* Chronic total occlusion
Source LEK Consulting based on interviews, research, analysis and third party data
Disclaimer: Third parties may not rely on the information provided
Soaring demand and market volume projected
